Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06622070
PHASE1
A Study of SPY002-072 in Healthy Volunteers
Sponsor: Spyre Therapeutics, Inc.
View on ClinicalTrials.gov
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single-dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-072 in healthy participants.
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY002-072 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
56
Start Date
2024-11-18
Completion Date
2026-08-08
Last Updated
2024-11-27
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
SPY002-072
Experimental
OTHER
Placebo
Placebo
Locations (2)
Spyre Site 2
Cypress, California, United States
Spyre Site 1
Montreal, Quebec, Canada